Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.45 |
| ▸ | AKT1S1 | Q96B36 | 6/20 | 0.38 |
| ▸ | LCK | P06239 | 5/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077975 | 0.81 | JAK3 (0.69) | JAK3LCKJAK2 | |
| SCHEMBL10324840 | 0.77 | AKT1S1 (0.39) | JAK3AKT1S1LCKJAK2 | |
| SCHEMBL1050610 | 0.73 | JAK3 (0.68) | JAK3LCKJAK2 | |
| SCHEMBL10325519 | 0.72 | JAK3 (0.52) | JAK3AKT1S1 | |
| SCHEMBL10325843 | 0.69 | JAK3 (0.41) | JAK3AKT1S1JAK2 | |
| SCHEMBL12568215 | 0.66 | JAK3 (0.65) | JAK3LCKJAK2 | |
| SCHEMBL12568381 | 0.66 | JAK3 (0.66) | JAK3LCKJAK2 | |
| SCHEMBL12568139 | 0.65 | JAK3 (0.66) | JAK3LCKJAK2 | |
| SCHEMBL16106114 | 0.65 | JAK3 (0.67) | JAK3LCKJAK2 | |
| SCHEMBL10324911 | 0.64 | JAK3 (0.39) | JAK3LCKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | JAK1, JAK2, JAK3 | JAK3 3/4885AKT1S1 1359/4885LCK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.